EX-10.1 EXCLUSIVE LICENSE AND SUPPLY AGREEMENT BY AND AMONG SURGICOUNT MEDICAL, INC. A CALIFORNIA CORPORATION AND A PLUS INTERNATIONAL, INC. A CALIFORNIA CORPORATIONExclusive License and Supply Agreement • February 2nd, 2007 • Patient Safety Technologies, Inc • Orthopedic, prosthetic & surgical appliances & supplies • California
AMENDMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT BETWEEN ICN PHARMACEUTICALS, INC. AND SCHERING-PLOUGH LTD. DATED JULY 28, 1995Exclusive License and Supply Agreement • January 3rd, 2002 • Ribapharm Inc • Pharmaceutical preparations
Certain information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed. EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • May 7th, 2019 • Eton Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT (this “Agreement”) is entered into as of February 8, 2019 (the “Effective Date”) by and between ETON PHARMACEUTICALS, INC., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park, Illinois, USA (“ETON”), and SINTETICA SA, a company number CHE-105.272.121 with offices at Penate 5, CH-6850 Mendrisio, Switzerland (“Sintetica”).
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...Exclusive License and Supply Agreement • October 8th, 2021 • Aura Biosciences, Inc. • Biological products, (no disgnostic substances) • Delaware
This Exclusive License and Supply Agreement (this “Agreement”) is dated January 31, 2014 (“Effective Date”) and is between LI-COR, Inc., a Nebraska corporation with a principal address of 4647 Superior Street, Lincoln, Nebraska 68504 (“LI-COR”), and Aura Biosciences, Inc., a Delaware corporation with a principal address of 85 Bolton Street, Cambridge, MA 02140 (“Aura”). LI-COR and Aura individually referred to herein as a “Party” and collectively as the “Parties”.
Portions of this exhibit have been omitted pursuant to a request for confidential treatment pursuant to 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2(b). The omitted portions, marked by [***], have been separately filed with the Securities and...Exclusive License and Supply Agreement • December 11th, 2015 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Amended and Restated Exclusive License and Supply Agreement (this “Agreement”) dated as of October 12, 2015 (the “Second Amendment Effective Date”) between Protalix Ltd., a limited liability company incorporated under the laws of Israel with offices located at 2 Snunit Street, Science Park, P.O.B. 455, Carmiel 20100, Israel (“Protalix”), and Pfizer Inc., a Delaware corporation with offices located at 235 East 42nd Street, New York, New York, 10017, U.S.A. (“Pfizer”).
SEVENTH SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study in JapanExclusive License and Supply Agreement • August 8th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Seventh Supplement (herein so called), effective as of February 28, 2022 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement”), is by and between Reata Pharmaceuticals Holdings, LLC, a limited liability company organized and existing under the laws of Delaware, USA, with an address at 5320 Legacy Drive, Plano, Texas 75024 (“Reata”), as assignee of the Original Agreement from Reata Pharmaceuticals, Inc., a Delaware corporation and the original signatory to the Original Agreement, as assignor (“Reata Pharmaceuticals”), and Kyowa Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • May 26th, 2005 • Oxis International Inc • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is entered into as of September 28, 2004 (the “Effective Date”) by and between OXIS INTERNATIONAL, a Delaware corporation (“OXIS”), located at 6040 N. Cutter Circle, Suite 317, Portland OR 97217 and HAPTOGUARD, INC., a Delaware corporation (“HaptoGuard”), located at 10 Rockefeller Plaza, Suite 1001, New York, New York 10020.
SECOND SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • June 23rd, 2017 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Second Supplement (herein so called), effective as of March 21, 2017 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.
AMENDMENT #2 TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • July 26th, 2006 • Oxis International Inc • Pharmaceutical preparations
This Amendment #2 to Exclusive License and Supply Agreement (“Amendment #2”) is made and entered into on the 19th day of July, 2006 (the “Effective Date”) by and between OXIS International, a Delaware corporation (“OXIS”), located at 6040 N. Cutter Circle, Suite 317, Portland, OR 97217 and HaptoGuard, Inc., a Delaware corporation, located at Park 80 West, Plaza II, Suite 200, Saddle Brook, NJ 07663 (“HaptoGuard”).
EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • February 7th, 2020 • Conatus Pharmaceuticals Inc. • Pharmaceutical preparations
This Exclusive License and Supply Agreement (the “LSA” or “Agreement”), dated as of September 30, 2016 (“Effective Date”), is by and between Histogen, Inc. (“Histogen”), a company organized and existing under the laws of Delaware, United States of America, and Pineworld Capital Limited, or an Affiliate of the foregoing (“Pineworld”), a company duly incorporated under the laws of the People’s Republic of China (each a “Party”, collectively the “Parties”).
EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • August 13th, 2015 • ChromaDex Corp. • Medicinal chemicals & botanical products • Minnesota
THIS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT (hereinafter referred to as the “Agreement”) is made on May 12, 2015 (the “Effective Date”) by and between Suntava, Inc. (hereinafter referred to as “Suntava”), a corporation with principal offices at 3290 St. Croix Trail, PO 268, Afton, MN 55001 and ChromaDex, Inc., with principal office at 10005 Muirlands Blvd., Suite G, Irvine, CA 92618 (hereinafter referred to as “ChromaDex”).
SIXTH SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • August 22nd, 2019 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Sixth Supplement (herein so called), effective as of August 22, 2019 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.
THIRD SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study (Alport Syndrome) in JapanExclusive License and Supply Agreement • December 7th, 2017 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Third Supplement (herein so called), effective as of December 6, 2017 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AND SUPPLY AGREEMENT by and between PFIZER INC. and PROTALIX LTD. November 30, 2009Exclusive License and Supply Agreement • February 26th, 2010 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Exclusive License and Supply Agreement (this “Agreement”) dated as of November 30, 2009 between Protalix Ltd., a limited liability company incorporated under the laws of Israel with offices located at 2 Snunit Street, Science Park, P.O.B 455, Carmiel 20100, Israel (“Protalix”), and Pfizer Inc., a Delaware corporation with offices located at 235 East 42nd Street, New York, New York, 10017, U.S.A. (“Pfizer”).
FOURTH SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Milestone payments, Supply price and Products manufacturingExclusive License and Supply Agreement • December 7th, 2017 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Fourth Supplement (herein so called), effective as of December 6, 2017 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AND SUPPLY AGREEMENT by and between VERSARTIS GmbH, VERSARTIS, INC. and TEIJIN LIMITEDExclusive License and Supply Agreement • November 4th, 2016 • Versartis, Inc. • Pharmaceutical preparations • California
This Exclusive License and Supply Agreement (this “Agreement”) effective as of August 5, 2016 (the “Effective Date”), is by and between Versartis GmbH, a corporation organized and existing under the laws of Switzerland, with an address at Muhlenberg 7, 4052 Basel, Switzerland (“GmbH”), and Versartis, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 4200 Bohannon Drive #250, Menlo Park, CA 94025, on behalf of itself and its Affiliates (collectively, “Versartis US”), (Versartis US and GmbH referred to herein collectively as “Versartis”), on the one hand, and Teijin Limited, a company organized and existing under the laws of Japan, with an address at 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo 100-8585, Japan (“Teijin”), on the other hand. Versartis and Teijin may be referred to herein each as a “Party” and collectively as the “Parties”.
FIFTH SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Milestone paymentsExclusive License and Supply Agreement • August 22nd, 2019 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Fifth Supplement (herein so called), effective as of August 22, 2019 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AND SUPPLY AGREEMENT by and between APPLIED THERAPEUTICS, INC. and MERCURY PHARMA GROUP LIMITED January 3, 2023Exclusive License and Supply Agreement • March 23rd, 2023 • Applied Therapeutics Inc. • Pharmaceutical preparations • England and Wales
This Exclusive License and Supply Agreement (this “Agreement”) dated as of January 3, 2023 is made by and between Applied Therapeutics, Inc., a company organized and existing under the laws of the State of Delaware in the U.S. with its head office at 545 5th Ave Suite 1400, New York, NY 10017 (“Applied”), and Mercury Pharma Group Limited (trading as Advanz Pharma Holdings), a company organized and existing under the laws of England and Wales with its head office at Capital House, 85 King William Street, London, EC4N 7BL, United Kingdom and registered under number 02330913 (“Advanz”) (each, a “Party” and collectively, the “Parties”).
AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • March 31st, 2014 • ULURU Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Exclusive License and Supply Agreement (this “Amendment”) is entered into and effective as of February 1, 2014 (the “Amendment Date”), by and between ULURU Inc., a Nevada corporation having an address at 4452 Beltway Drive, Addison, TX 75001, USA (“ULURU”) and ALTRAZEAL AG, a corporation organized and existing under the Laws of Switzerland and having an address at Bosch 71, CH 6331 Hunenberg (“ALTRAZEAL AG”) (each of ULURU and ALTRAZEAL AG, a “Party” or together, the “Parties”).
SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study (CTD-PAH) in JapanExclusive License and Supply Agreement • March 22nd, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Supplement (herein so called), effective as of, January 1, 2016 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.
THIRD SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study (Alport Syndrome) in JapanExclusive License and Supply Agreement • February 28th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Third Supplement (herein so called), effective as of December 6, 2017 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AND SUPPLY AGREEMENT dated as of September 30, 2013 between ULURU INC. And ALTRAZEAL AGExclusive License and Supply Agreement • November 14th, 2013 • Uluru Inc. • Pharmaceutical preparations • Delaware
THIS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT (this "Agreement") is made and entered into as of this 30th day of September, 2013 (the "Effective Date"),
EXCLUSIVE LICENSE and SUPPLY AGREEMENT by and between REATA PHARMACEUTICALS, INC. and KYOWA HAKKO KIRIN CO. LTD.Exclusive License and Supply Agreement • February 28th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Exclusive License and Supply Agreement (this “ Agreement ”) effective as of December 24, 2009 (the “ Effective Date ”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“ Reata ”), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (“ Kyowa Kirin ”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “ Party ” and collectively as the “ Parties .”
Portions of this exhibit have been omitted pursuant to a request for confidential treatment pursuant to 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2(b). The omitted portions, marked by [***], have been separately filed with the Securities and...Exclusive License and Supply Agreement • March 6th, 2018 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Exclusive License and Supply Agreement (this “Agreement”) dated as of the 17th day of October, 2017 is made by and between Protalix Ltd., a limited liability company incorporated under the laws of Israel with offices located at 2 Snunit Street, Science Park, P.O. Box 455, Carmiel 20100, Israel (“Protalix”), and Chiesi Farmaceutici S.p.A., a company incorporated under the laws of Italy with offices located at Largo F. Belloli, 11/A - 43122 Parma, Italy (“Chiesi”) (each, a “Party” and collectively, the “Parties”).
EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • August 9th, 2017 • PTC Therapeutics, Inc. • Pharmaceutical preparations
THIS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT (this “Agreement”) is made and entered into as of May 12, 2015 (the “Effective Date”), by and between Faes Farma, S.A., a corporation (sociedad anónima) organized under the Laws of Spain and having offices located at Avenida Autonomía 10, 48.940 Leioa (Biscay) Spain (“Faes”), and Marathon Pharmaceuticals, LLC, a limited liability company organized under the Laws of the State of Delaware (U.S.A.) and having offices located at 1033 Skokie Boulevard, Suite 600, Northbrook, Illinois 60062 U.S.A. (“Marathon”). Faes and Marathon are sometimes individually referred to herein as a “Party” and collectively as the “Parties”.
Exclusive License and Supply Agreement by and between Cardiome Pharma Corp. and Correvio International Sárl and SteadyMed Ltd.Exclusive License and Supply Agreement • August 13th, 2015 • SteadyMed Ltd. • Pharmaceutical preparations • New York
This Exclusive License and Supply Agreement (this “Agreement”) is made as of 28th June 2015 (the “Effective Date”), by and between CARDIOME PHARMA CORP., a company duly incorporated under the laws of Canada, with its principal place of business at 1441 Creekside Drive, 6th Floor, Vancouver BC V6J 4S7 and Correvio International Sàrl, a company duly incorporated and existing under the laws of Switzerland, with its principal place of business at Rue des Alpes 21, 1201 Geneva, Switzerland (hereinafter collectively referred to as “Cardiome”), and STEADYMED LTD., a company organized and existing under the laws of Israel with its principal place of business at 5 Oppenheimer Street, Rehovot 7670105, Israel (“SteadyMed”). Each of Cardiome and SteadyMed is referred to individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • August 12th, 2022 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • England and Wales
THIS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT (“Agreement”) is made effective as of the 7th day of April, 2022 (the “Effective Date”), by and between Immedica Pharma AB, a corporation organized and existing under the laws of Sweden with registration number, 556835-6322 and offices at Norrtullsgatan 15, SE 113 29 Stockholm, Sweden (“IMMEDICA”) and Actinium Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware and with offices at 275 Madison Avenue, 7th Floor, New York, NY 10016, U.S.A. (“LICENSOR”). IMMEDICA and LICENSOR may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • May 13th, 2011 • Diversified Opportunities, Inc. • Services-prepackaged software • California
This Exclusive License and Supply Agreement (“Agreement”) is made and entered into as of January 1, 2011, by and between The Sugar Cane Paper Co., Ltd., a Hong Kong limited company (“SCP”), and SugarMade, Inc., a California corporation (“SugarMade”) with respect to the following facts:
